All In MedTech

Company

Surmodics

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

From SEC filings.

We found no SEC financing filings under the name Surmodics, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is part of the paid tier

For Surmodics we have 136 government grants totalling $23.5M.

It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

Latest FDA decisions

The 8 newest of 14 since 2015.

Search the Clearance Tracker

11 more FDA decisions with a free account

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT05868161 · 500 participants (planned) · Start Apr 18, 2023 · Primary completion May 31, 2026

    Device: Pounce Thrombectomy System · For: Peripheral Arterial Disease; Acute Limb Ischemia

    Sites: Peoria, Illinois; Munster, Indiana; Baton Rouge, Louisiana · 9 sites in all

  • NCT03241459 · 446 participants · Start Oct 23, 2017 · Primary completion Sep 15, 2020

    Device: Surmodics SurVeil DCB; Medtronic IN.PACT Admiral DCB · For: Peripheral Arterial Disease; Peripheral Vascular Disease; Artery Disease, Peripheral and 1 more

    Sites: Birmingham, Alabama; Foley, Alabama; Gilbert, Arizona · 63 sites in all

  • NCT03734679 · 12 participants · Start Dec 5, 2018 · Primary completion Feb 19, 2020

    Device: SurVeil Drug Coated Balloon · For: Hemodialysis Access Failure

    Sites: Randwick, Australia; Auckland, New Zealand

3 more trials with a free account

Reports received

2

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

2

100% of reports

Injury reports

0

0.0% of reports

Death reports

0

0.0% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 231100
Jan 240000
Feb 240000
Mar 240000
Apr 240000
May 240200
Jun 240000
Jul 240000
Aug 240000
Sep 240000
Oct 240000
Nov 240200
Dec 240000
Jan 250000
Feb 250000
Mar 250000
Apr 250100
May 250000
Jun 251000
Jul 250100
Aug 251000
Sep 251000
Oct 251100
Nov 251000
Dec 251000
Jan 260000
Feb 260000
Mar 260000
Apr 260000
May 260000
Jun 260000
Jul 260000
Aug 260000
Sep 260000
Oct 260000
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recalls under this name in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.